The grants received by department members are listed as follows: the members of the department, the
title of the project, the sponsor, and the $'s expended at the London Health Sciences Centre in the fiscal period.
Cortese L. Olanzapine versus haloperidol and Risperidone in the treatment of schizphrenia and related psychotic
disorders. Eli Lilly. $66000.
Forchuk C. Post-operative arm massage: a support for women with lumph nood dissection and their families. LHSC
Health Services Research Fund. $4500.
Forchuk C, Jewell J, Tweedell D, Savedia V, Shah D, MacLean T. A qualitative analysis of the experiences of
clients, families and care providers. Ontario Hospital Nurses'Alumnae Association, Canadian Nurses Foundation,
Pharmaceutical manufacturers of Canada, LHSC Internal Research Fund. $10000.
Forchuk C, Martin M, Dhawan R, Yamashita M, Garner M, Tileman M. Exploring the influence of the case manager.
LHSC Health Services Research Fund. $1962.
Malla A. Stress management in schizophrenia: a controlled trial. LHSC Internal Research Fund. $12500.
Malla A. A multicentre study of Ipsapirone outpatients with moderate to severe major depressive disorder. Bayer
Corp. $33401.
Malla A. Research bulletin. Hoechst-Roussel Canada Inc. $5000.
Malla A. Economic and quality of life evaluation of risperidone. Janssen Pharmaceuticals Inc. $6000.
Malla A, Norman R. Voluntary movement disorders in schizophrenia. Janssen Pharmaceuticals Inc. $10000.
Malla A. Oral ziprasidone and haloperidol in the maintenance treatment of outpatients with schizophrenia or
schizoaffective disorder. Pfizer Canada Inc. $140938.
Malla A. Psychiatry research support. Departmental Funds. $7359.
Malla A. A multicentre comparison of seroquel in the treatment of subjects with acute exacerbation of subchronic
or chronic schizophrenia. Zeneca Pharma Inc. $30845.
Malla A. Community liaison and first episode psychosis program. Zeneca Pharma Inc. $48000.
Malla A, Aguilar Q, Carnahan H. Voluntary movement psychopathology in schizophrenia. Victoria Hospital Research
Development Fund. $11500.
Malla A. A multicentre trial to compare the effects of seroquel and haloperidol treatment strategies on treatment
outcomes. Zeneca Pharma Inc. $92560.
Manchanda R, Williamson P, Malla A. A multicentre comparison of dose and dose regimen of seroquel in the treatment
of subjects with acute exacerbation of subchronic or chronicschizophrenia. Zeneca Pharma Inc. $27000.
Manchanda R, Malla A, Cortese L. McCrank E, Voruganti L. A study of Ipsapirone controlled release (CR) versus
placebo in outpatients with moderate to severe major depressive disorder (MMD). Miles Canada Inc. $51512.
Max P. Efficacy and safety of venlafaxine extended release verses fluoxetine in depressed outpatients with
concomitant anxiety. Wyeth Ayerst Research. $20865.
Nicholson IR, Norman R, Malla A, Neufeld R. Confirmatory factor analysis of opposing models for schizophrenic
symptomatology. Research Committee, UWO. $1000.
Norman R, Malla A, Neufeld R, McLean T, Cheung S, Cortese L, Diaz K, Rickwood A. Evaluation of a stress management
program for individuals with schizophrenia. Health and Welfare Canada, Natural Health Research Development Program.
$24000.
Norman R. Evaluation of a stress management program for individuals with schizophrenia. Ontario Mental Health
Foundation. $68000.
Norman R, Malla A, Neufeld R, Rajakumar N. An investigation of the effects of stress on cognition in schizophrenia.
LHSC Internal Research Fund. $12000.
Norman R. Utility measurement and cost analysis in schizophrenia. University Incentives Research Fund. Ministry
of Education and Training and Janssen Pharmaceutical. $24484.
Norman R. Utility measurement and cost analysis in schizophrenia. Departmental Research Funds. $2500.
Oyewumi LK, Freeman DL, Rieder MJ. Invitro toxicity of neuroleptics. University Hospital Pooled Research Fund.
$6500.
Persad E. Voluntary movement dysfunction and syndromes in schizophrenia. Canadian Psychiatric Research Foundation.
$7000.
Persad E. Movement disorders in schizophrenia. Departmental Funds. $3000.
Persad E. An open label assessment of the clinical utility of venlanfaxine tablets in depression. Wyeth-Ayerst
Research. $14500.
Persad E, Sharma V. Study of efficacy and safety of venlafaxine extended release verses fluoxetine in depressed
outpatients with concomitant anxiety. Wyeth-Ayerst Research. $97500.
Rajakumar N. Postpubertal effects of excitotoxic lesions of the mediodorsal nuceus of the thalamus as neonates:
an animal model of schizophreniz. Ontario Mental Health Foundation. $59907.
Rajakumar N. Postpubertal effects of excitotoxic lesions of the mediocorsal nucleus of the thalamus as neonates:
animal model of schizophrenia. University of Western Ontario. Faculty of Medicine. $4000.
Rajakumar N. Co-grafts of growth factor transfected cell lines and fetal dopaminergic neurons: a novel strategy
for the treatment of Parkinson's Disease. J.P. Bickell Foundation. $17900.
Rajakumar N. Changes in striatal mRNA expression following chronic neuroleptic administration in the rat. Department
of Psychiatry. $9975.
Rajakumar N. Changes in striatal mRNA expression following chronic neuroleptic administration in the rat. Vice-President,
UWO Competition. $5000.
Voruganti L, Norman R, Dhawan R. Utility measurement and cost utility analysis in Schizophrenia. Janssen Pharmaceuticals/URIF.
$48967.
Williamson P, Drost D, Carr TJ, Malla AK, Kraus, RD, Merskey H. Candidate neuronal circuits in schizophrenia.
Medical Research Council of Canada. $130294.
Williamson P. 1H & 31P Magnetic resonance spectroscopy in schizophrenia. National Institute of Health.
$302551.
Williamson P, Drost D, Thompson T, Carr T. Nuclear magnetic resonance spectroscopy in schizophrenia. Low-Beer
(ELJB) Foundation. $136000.
Williamson P, Drost D. H and P magnetic resonance spectroscopy in schizophrenia. The National Institute of
Mental Health, USA. $131756 US.
Williamson P, Drost D. H and P magnetic resonance spectroscopy in schizophrenia. Medical Research Council of
Canada. $102996.
Williamson P. A study evaluating the safety and efficacy in the maintance treatment of outpatients with schizophrenia
or schizoaffective disorder. Pfizer Inc., USA. $197800.
Williamson P. A study in the safety and efficacy of oral ziprasidone and haloperidol of outpatients with schizophrenia
or schizoaffective disorder who have successfully completed protocol. Pfizer Inc., USA. $16800.
Yamashita M, Forchuk C, Mound B. An investigation into nursing practice models. Sigma Theta Tau, Iota Omicron
Chapter. $500.
